Full Length Research Paper
References
|
Adams KF, Butler J, Patterson JH, Gattis Stough W, Bauman JL, van Veldhuisen DJ, Schwartz TA, Sabbah H, Mackowiak JI, Ventura HO, Ghali JK (2016). Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. European Journal of Heart Failure 18(8):1072 1081. |
|
|
Adams KF, Gheorghiade M, Uretsky BF, Young JB, Ahmed S, Tomasko L, Packer M (1997). Patients with mild heart failure worsen during withdrawal from digoxin therapy. Journal of the American College of Cardiology 30(1):42 48. |
|
|
Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M (2006). Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. European Heart Journal 27(2):178 186. |
|
|
Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola SH (2009). Effectiveness of Digoxin in Reducing One-Year Mortality in Chronic Heart Failure in the Digitalis Investigation Group Trial. The American Journal of cardiology 103(1):82 87. |
|
|
Al-Khateeb M, Qureshi WT, Odeh R, Ahmed AM, Sakr S, Elshawi R, Bdeir, MB, Al-Mallah MH (2017). The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. International Journal of Cardiology 228:214 218. |
|
|
Andrey JL, Romero S, García-Egido A, Escobar MA, Corzo R, Garcia-Dominguez G, Lechuga V, Gómez, F (2011). Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. International Journal of Clinical Practice 65(12):1250 1258. |
|
|
Bakris GL, Fonseca,V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, Anderson KM, Bell DSH, GEMINI Investigators (2004). Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 292(18):2227 2236. |
|
|
Bamba-Kamagate D, Coulibaly I, Soya E, Traore F, N'Choh-Mattoh MP, Koffi F, Tanoh M (2016). Drug Prescription Analysis at Hospital Discharge for Heart Failure Patients at the Institute of Cardiology of Abidjan. World Journal of Cardiovascular Diseases 6(3):3. |
|
|
Bamba-Kamagate D, Traore F, Coulibaly I, Die Kacou H, Abouo N'dori R (2013). Intoxication digitalique et digoxinémie normale: 5 cas observés à l'Institut de Cardiologie d'Abidjan. Revue Internationale des Sciences Médicales d'Abidjan 15(3):178 180. |
|
|
Digitalis Investigation Group (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. The New England Journal of Medicine 336(8):525 533. |
|
|
Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L, Rauzy B, Cosnay P, Babuty D, Charbonnier B (2009). Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. The American Journal of Cardiology 103(2):248 254. |
|
|
Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS (2013). Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circulation. Cardiovascular Quality and Outcomes 6(5):525 533. |
|
|
Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJV, Ahmed A (2013). Effect of oral digoxin in high-risk heart failure patients: A pre-specified subgroup analysis of the DIG trial. European Journal of Heart Failure 15(5):551 559. |
|
|
Hashim T, Elbaz S, Patel K, Morgan CJ, Fonarow GC, Fleg JL, McGwin G, Cutter GR, Allman RM, Prabhu SD, Zile MR, Bourge RC, Ahmed A (2014). Digoxin and 30-Day All-Cause Hospital Admission in Older Patients with Chronic Diastolic Heart Failure. The American Journal of Medicine 127(2):132 139. |
|
|
Katz A, Maor E, Leor J, Klempfner R (2016). Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. International Journal of Cardiology 221:198 204. |
|
|
Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF (2003). Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? Journal of the American College of Cardiology 42(11):1944 1951. |
|
|
Kouamé K (2018). Analyse du parcours de soins des patients insuffisants cardiaques à l'Institut Cardiologique d'Abidjan [Medical Thesis]. Félix Houphouet Boigny University. |
|
|
Lopes D, Sartori C (2018). Comment utiliser correctement les β-bloquants?? Revue medicale suisse 14(628):2097-2101. |
|
|
Lu HT, Kam J, Nordin RB, Khelae SK, Wang JM, Choy CN, Lee CY (2016). Beta-blocker use and risk of symptomatic bradyarrhythmias: A hospital-based case-control study. Journal of Geriatric Cardiology 13(9):749 759. |
|
|
Madelaire C, Schou M, Nelveg-Kristensen KE, Schmiegelow M, Torp-Pedersen C, Gustafsson F, Køber L, Gislason G (2016). Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. International Journal of Cardiology 221:944 950. |
|
|
Maiga AK, Doumbia CT, Fofana D, Kante F, Diallo S, Daffe S, Terra AW, Sidibé S, Touré M, Bâ HO, Diarra MB (2019). Les Bêtabloquants dans le Traitement de l'Insuffisance Cardiaque dans le Service de Cardiologie du CHU Mère-Enfant (CHU-ME) «?Le Luxembourg?». Health Sciences and Disease 20(6):6. |
|
|
Martin N, Manoharan K, Thomas J, Davies C, Lumbers RT (2018). Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. The Cochrane Database of Systematic Reviews 6(6):CD012721. |
|
|
Migaj J, Ka?u?na-Oleksy M, Nessler J, Opolski G, Crespo-Leiro MG, Maggioni AP, Grajek S, Ponikowski P, Dro?d? J Straburzy?ska-Migaj E (2018). Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. Kardiologia Polska 76(7):1064 1072. |
|
|
Nassiet S (2015). Physiopathologie de l'insuffisance cardiaque, traitements et éducation thérapeutique du patient à l'officine [Pharmacy Thesis, Bordeaux University]. |
|
|
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, ESC Scientific Document Group (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 37(27):2129 2200. |
|
|
Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM (2003). Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289(7):871 878. |
|
|
Rathore SS., Wang Y, Krumholz HM (2002). Sex-based differences in the effect of digoxin for the treatment of heart failure. The New England Journal of Medicine 347(18):1403 1411. |
|
|
Yves J (2007). Objectif thérapeutique de digoxinémie dans l'insuffisance cardiaque. Repère pratique. |
|
|
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH, Steeds RP, Townend J, Kotecha D (2015). Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data. BMJ (Clinical Research Ed.), 351 p h4451. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
